tesamorelin/ipamorelin stack: Frequently asked questions

GH antagonises insulin signaling, causing transient insulin resistance in 5–8% of users. Fasting glucose may rise 5–15 mg/dL above baseline during active cycles. This is a known pharmacological effect documented in tesamorelin prescribing information and typically resolves within four weeks of discontinuation. If fasting glucose exceeds 110 mg/dL or HbA1c rises above 5.7%, reduce tesamorelin to 1mg daily and retest after two weeks. Pre-diabetic or diabetic individuals should monitor glucose weekly and adjust protocol dosing in consultation with a prescribing physician.

Reduce the tesamorelin dose to 1.5mg daily while maintaining ipamorelin at 300mcg. Joint stiffness and transient oedema occur in 10–15% of users during the first 10–14 days as GH elevates IGF-1 (insulin-like growth factor-1), which increases sodium retention and synovial fluid production. These effects resolve spontaneously as the kidneys upregulate aldosterone clearance. If symptoms persist beyond three weeks, cycle off for 7–10 days to allow receptor sensitivity to reset, then resume at the reduced dose.

No. Administer the next scheduled dose at the standard amount. Do not compensate for missed doses. Doubling doses disrupts the pulsatile GH pattern the protocol relies on and increases the risk of receptor desensitisation. Missing 2–3 doses per month has minimal impact on cumulative VAT reduction over a 26-week cycle, but irregular dosing (e.g., dosing every other day instead of daily) reduces efficacy by approximately 40% compared to consistent daily administration.

Discard it immediately. Temperature excursions above 8°C cause irreversible denaturation of the peptide's tertiary structure. The three-dimensional folding that determines receptor binding affinity. Tesamorelin and ipamorelin are both synthetic analogs with specific amino-acid sequences that lose biological activity when heat disrupts hydrogen bonding and disulfide bridges. Unlike small-molecule drugs, peptides cannot 'refold' once denatured. The structural damage is permanent. Visual inspection cannot detect this degradation; the solution will appear clear and unchanged even when completely inactive. Research using temperature-compromised peptides produces null results not because the protocol failed, but because the compound was no longer pharmacologically active.

Verify peptide storage conditions, reconstitution technique, and injection timing before concluding the protocol is ineffective. The most common cause of null results is peptide degradation from improper storage or reconstitution errors. Particularly injecting bacteriostatic water directly onto the lyophilized cake, which mechanically shears peptide chains. Second, confirm injection technique: subcutaneous depth (not intramuscular), slow administration, and site rotation. Third, assess timing: ipamorelin administered immediately post-meal during peak insulin secretion shows blunted GH response due to insulin's inhibitory effect on GH release. If all variables check out and the peptides are from a verified source like Real Peptides, individual response variance may explain the outcome. Approximately 10–15% of subjects in GH secretagogue studies show minimal response due to receptor polymorphisms or pre-existing GH resistance.

Reduce the dose to 100–150mcg and assess tolerance over 5–7 days before escalating. Ipamorelin is remarkably clean compared to earlier ghrelin mimetics, but individual sensitivity to rapid GH elevation varies. Nausea typically occurs when GH secretion spikes faster than peripheral tissues can clear the resulting insulin-like growth factor 1 (IGF-1) and free fatty acids. A transient mismatch between secretion and clearance. Administering ipamorelin with a small amount of food (20–30g carbohydrate) can blunt the nausea without significantly impairing GH release. If symptoms persist beyond two weeks at reduced dose, discontinue and consult the supervising researcher or clinician.

Rotate sites more frequently and slow injection speed to 10–15 seconds per dose. Subcutaneous tissue trauma from repeated injections at the same site causes localized inflammation and lipohypertrophy. Thickened fat tissue that impairs peptide absorption. The redness typically resolves within 48–72 hours if the site is rested. Persistent lumps suggest lipohypertrophy and require complete site rotation for 4–6 weeks while the tissue remodels. Acceptable injection zones include: lower abdomen (2 inches lateral to navel), anterior/lateral thigh, and deltoid. Avoid injecting within 1 inch of previous injection sites for at least 72 hours. If redness spreads, becomes warm to touch, or is accompanied by systemic symptoms (fever, malaise), discontinue and seek medical evaluation. This may indicate infection rather than mechanical trauma.